Llwytho...
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
BACKGROUND: Manipulation of immune checkpoints such as CTLA4 or PD-1 with targeted antibodies has recently emerged as an effective anticancer strategy in multiple malignancies. Sarcomas are a heterogeneous group of diseases in need of more effective treatments. Different subtypes of soft tissue and...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Clin Sarcoma Res |
|---|---|
| Prif Awduron: | , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BioMed Central
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5200964/ https://ncbi.nlm.nih.gov/pubmed/28042471 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13569-016-0064-0 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|